An Assessment of the Absolute and Relative Bioavailability of Subcutaneous Doses of LY3074828 When Coadministered With LY9999QS to Healthy Subjects

Trial Profile

An Assessment of the Absolute and Relative Bioavailability of Subcutaneous Doses of LY3074828 When Coadministered With LY9999QS to Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs LY900021 (Primary) ; Mirikizumab (Primary)
  • Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 21 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top